{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:16:18Z","timestamp":1783692978806,"version":"3.55.0"},"reference-count":50,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Immune thrombocytopenia (ITP) is an autoimmune disease characterized by the autoantibody-mediated destruction of platelets. The treatment of ITP aims to maintain a sufficient platelet count to prevent bleeding. First-line treatment options include corticosteroids and intravenous immunoglobulin (IVIg), while second-line treatments include splenectomy, rituximab and other immunosuppressive agents, and thrombopoietin (TPO) receptor agonists. This study aims to discuss the treatment methods and results from 100 patients with ITP at the Mu\u011fla Training and Research Hospital through a pharmacological approach. Materials and Methods: Demographic characteristics, clinical findings, bone marrow aspiration and biopsy results, and treatments and treatment responses at the time of diagnosis of the 100 patients with ITP who were treated and followed up in the period 2015\u20132023 were evaluated retrospectively. Results: In the third month after treatment, the overall response percentage was 100% in patients who received steroids only and 88% in patients who received IVIg treatment alone or in combination with steroids (p &gt; 0.05). The most preferred second-line treatments were splenectomy (41%), eltrombopag (26%), and rituximab (10%). Bone marrow biopsy was performed in 54% of patients, where 35.1% showed increased megakaryocytes, 44.4% adequate megakaryocytes, and 14.8% decreased megakaryocytes. It is noted that eltrombopag and rituximab, in particular, yield higher complete remission rates than immunosuppressive drugs. Conclusions: Considering the side effects of immunosuppressive medications, IVIg, splenectomy, and steroid therapy, the use of new agents such as eltrombopag, which are easily tolerated and have a lower risk of side effects, is expected to increase.<\/jats:p>","DOI":"10.3390\/medicina60071153","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T12:29:43Z","timestamp":1721219383000},"page":"1153","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Retrospective Evaluation of Survival and Prognostic Factors in Immune Thrombocytopenia: A Single-Center and Cross-Sectional Study"],"prefix":"10.3390","volume":"60","author":[{"given":"G\u00f6khan","family":"Pekta\u015f","sequence":"first","affiliation":[{"name":"Division of Hematology, Faculty of Medicine, Mu\u011fla S\u0131tk\u0131 Ko\u00e7man University, 48000 Mu\u011fla, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130brahim Asaf","family":"Uncu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Faculty of Medicine, Mu\u011fla S\u0131tk\u0131 Ko\u00e7man University, 48000 Mu\u011fla, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelda","family":"Dere","sequence":"additional","affiliation":[{"name":"Department of Medical Pathology, Faculty of Medicine, Mu\u011fla S\u0131tk\u0131 Ko\u00e7man University, 48000 Mu\u011fla, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeyma","family":"\u00d6nc\u00fc","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacology, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03200 Afyonkarahisar, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve Becit","family":"K\u0131z\u0131lkaya","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Faculty of Pharmacy, Afyonkarahisar Health Sciences University, 03200 Afyonkarahisar, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6khan","family":"Sadi","sequence":"additional","affiliation":[{"name":"Department of Biology, K.O. Science Faculty, Karamanoglu Mehmetbey University, 70100 Karaman, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Bilgehan","family":"Pekta\u015f","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacology, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03200 Afyonkarahisar, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-023-01401-z","article-title":"How We Treat Primary Immune Thrombocytopenia in Adults","volume":"16","author":"Liu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101112","DOI":"10.1016\/j.blre.2023.101112","article-title":"Primary and Secondary Immune Thrombocytopenia (ITP): Time for a Rethink","volume":"61","author":"Provan","year":"2023","journal-title":"Blood Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.thromres.2020.01.020","article-title":"Why Do Patients with Immune Thrombocytopenia (ITP) Experience Lower Bleeding Events despite Thrombocytopenia?","volume":"187","author":"Boulware","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.revmed.2020.05.018","article-title":"New Insights into the Epidemiology of Immune Thrombocytopenia in Adult Patients: Impact for Clinical Practice","volume":"42","author":"Moulis","year":"2021","journal-title":"Rev. M\u00e9d. Interne"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2017.05.010","article-title":"Epidemiology and Management of Primary Immune Thrombocytopenia: A Nationwide Population-Based Study in Korea","volume":"155","author":"Lee","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/CIA.S369574","article-title":"Older Adults and Immune Thrombocytopenia: Considerations for the Clinician","volume":"18","author":"Crickx","year":"2023","journal-title":"Clin. Interv. Aging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3324\/haematol.2016.146373","article-title":"Immune Thrombocytopenia in Adults: A Prospective Cohort Study of Clinical Features and Predictors of Outcome","volume":"101","author":"Nordon","year":"2016","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3109\/09537104.2013.845875","article-title":"Megakaryocyte Morphology and Its Impact in Predicting Response to Steroid in Immune Thrombocytopenia","volume":"25","author":"Tripathi","year":"2014","journal-title":"Platelets"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.lpm.2014.02.010","article-title":"Immune Thrombocytopenic Purpura: Major Progress in Knowledge of the Pathophysiology and the Therapeutic Strategy, but Still a Lot of Issues","volume":"43","author":"Godeau","year":"2014","journal-title":"Presse Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of Terminology, Definitions and Outcome Criteria in Immune Thrombocytopenic Purpura of Adults and Children: Report from an International Working Group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/09537104.2018.1475637","article-title":"Megakaryocyte Apoptosis in Immune Thrombocytopenia","volume":"29","author":"Vrbensky","year":"2018","journal-title":"Platelets"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 Guidelines for Immune Thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/jth.14227","article-title":"Risk Factors for Bleeding, Including Platelet Count Threshold, in Newly Diagnosed Immune Thrombocytopenia Adults","volume":"16","author":"Germain","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/jth.14446","article-title":"Cardiovascular and Bleeding Outcomes in a Population-based Cohort of Patients with Chronic Immune Thrombocytopenia","volume":"17","author":"Adelborg","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/JBM.S358993","article-title":"Clinical Epidemiology, Treatment Outcome and Mortality Rate of Newly Diagnosed Immune Thrombocytopenia in Adult Multicentre Study in Malaysia","volume":"13","author":"Hamzah","year":"2022","journal-title":"J. Blood Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2015.1.237","article-title":"Bleeding Complications in Immune Thrombocytopenia","volume":"2015","author":"Arnold","year":"2015","journal-title":"Hematology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 Evidence-Based Practice Guideline for Immune Thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/2040620718798798","article-title":"Eltrombopag-Based Combination Treatment for Immune Thrombocytopenia","volume":"9","year":"2018","journal-title":"Ther. Adv. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/09537104.2019.1708300","article-title":"A Megakaryocyte Morphological Classification-Based Predictive Model for Steroid Sensitivity in Primary Immune Thrombocytopenia","volume":"31","author":"Zhu","year":"2020","journal-title":"Platelets"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12185-014-1533-y","article-title":"Eltrombopag Therapy in Newly Diagnosed Steroid Non-Responsive ITP Patients","volume":"99","author":"Tripathi","year":"2014","journal-title":"Int. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood-2005-12-015222","article-title":"Therapy with High-Dose Dexamethasone (HD-DXM) in Previously Untreated Patients Affected by Idiopathic Thrombocytopenic Purpura: A GIMEMA Experience","volume":"109","author":"Mazzucconi","year":"2007","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000445420","article-title":"A Randomized Trial of Daily Prednisone versus Pulsed Dexamethasone in Treatment-Na\u00efve Adult Patients with Immune Thrombocytopenia: EIS 2002 Study","volume":"136","author":"Matschke","year":"2016","journal-title":"Acta Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/vox.12467","article-title":"New Aspects on the Efficacy of High-dose Intravenous Immunoglobulins in Patients with Autoimmune Thrombocytopenia","volume":"112","author":"Mayer","year":"2017","journal-title":"Vox Sang."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ajh.21500","article-title":"Cost and Mortality Associated with Hospitalizations in Patients with Immune Thrombocytopenic Purpura","volume":"84","author":"Danese","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bjh.12869","article-title":"Twenty-year Mortality of Adult Patients with Primary Immune Thrombocytopenia: A Danish Population-based Cohort Study","volume":"166","author":"Frederiksen","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2165\/11319260-000000000-00000","article-title":"Immunosuppressive Drugs in Kidney Transplantation","volume":"69","year":"2009","journal-title":"Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jnci\/djh118","article-title":"Skin Cancers and Non-Hodgkin Lymphoma among Users of Systemic Glucocorticoids: A Population-Based Cohort Study","volume":"96","author":"Sorensen","year":"2004","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1056\/NEJMoa030254","article-title":"Initial Treatment of Immune Thrombocytopenic Purpura with High-Dose Dexamethasone","volume":"349","author":"Cheng","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune Thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_32","first-page":"206","article-title":"Intravenous Treatment with Gammaglobulin in Adults with Immune Thrombocytopenic Purpura: Review of the Literature","volume":"52","author":"Bussel","year":"1987","journal-title":"Vox Sang."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/1076029614526639","article-title":"Immune Thrombocytopenia","volume":"21","author":"Abadi","year":"2015","journal-title":"Clin. Appl. Thromb."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1002\/pbc.24341","article-title":"Positioning New Treatments in the Management of Immune Thrombocytopenia","volume":"60","author":"Arnold","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1177\/1076029616663849","article-title":"Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia: Meta-Analysis of Randomized Controlled Trials","volume":"23","author":"Elgebaly","year":"2017","journal-title":"Clin. Appl. Thromb."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for Management of Chronic Immune Thrombocytopenia (RAISE): A 6-Month, Randomised, Phase 3 Study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"key":"ref_37","first-page":"40","article-title":"Successful Discontinuation of Eltrombopag after Complete Remission in Patients with Primary Immune Thrombocytopenia","volume":"90","author":"Pascual","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and Efficacy of Long-Term Treatment of Chronic\/Persistent ITP with Eltrombopag: Final Results of the EXTEND Study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","article-title":"Rituximab in the Treatment of Immune Thrombocytopenia: What Is the Role of This Agent in 2019?","volume":"104","author":"Lucchini","year":"2019","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1365-2141.2003.04211.x","article-title":"Long-term Follow-up of Chronic Autoimmune Thrombocytopenic Purpura Refractory to Splenectomy: A Prospective Analysis","volume":"120","author":"Bourgeois","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000206184","article-title":"Danazol in Idiopathic Thrombocytopenic Purpura","volume":"74","author":"Almagro","year":"1985","journal-title":"Acta Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000205948","article-title":"Danazol Therapy in Refractory Chronic Immune Thrombocytopenic Purpura","volume":"77","author":"Mazzucconi","year":"1987","journal-title":"Acta Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/ejh.13144","article-title":"Immune Thrombocytopenia: Effectiveness of Frontline Steroids and Comparison of Azathioprine, Splenectomy, and Rituximab as Second-line Treatment","volume":"101","author":"Chang","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood.V85.2.351.351","article-title":"Pulse Cyclophosphamide Therapy for Refractory Autoimmune Thrombocytopenic Purpura [See Comments]","volume":"85","author":"Reiner","year":"1995","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.2830010111","article-title":"Treatment of Refractory Thrombocytopenic Purpura with Cyclophosphamide","volume":"1","author":"Verlin","year":"1976","journal-title":"Am. J. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00277-016-2791-y","article-title":"Cyclosporin A for Persistent or Chronic Immune Thrombocytopenia in Children","volume":"95","author":"Liu","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1745-7254.2005.00088.x","article-title":"Mycophenolate Mofetil as a Treatment for Refractory Idiopathic Thrombocytopenic Purpura","volume":"26","author":"Zhang","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1034\/j.1600-0609.2003.00076.x","article-title":"Mycophenolate Mofetil (MMF) for the Treatment of Steroid-resistant Idiopathic Thrombocytopenic Purpura","volume":"70","author":"Hou","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.13622","article-title":"Mycophenolate Mofetil Therapy for Severe Immune Thrombocytopenia","volume":"171","author":"Taylor","year":"2015","journal-title":"Br. J. Haematol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/7\/1153\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:18:23Z","timestamp":1760109503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/7\/1153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["medicina60071153"],"URL":"https:\/\/doi.org\/10.3390\/medicina60071153","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]}}}